Natural History of Advanced Chronic Liver Diseases
Launched by CHINESE UNIVERSITY OF HONG KONG · Jun 25, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the natural progress of advanced chronic liver disease, including cirrhosis, over a long period of time. The goal is to better understand how liver problems develop and what health events or complications might occur, especially those related to the liver. People with this condition will be followed for up to 10 years, with yearly check-ups using a painless test called transient elastography, which measures liver stiffness to monitor liver health.
Adults aged 18 and older who have confirmed advanced liver disease—either through specific liver stiffness measurements or signs seen on ultrasound and related examinations—may be eligible to join. However, people with a history of liver cancer, liver transplant, or certain other serious health issues are not eligible. Participants can expect regular yearly visits for liver testing and monitoring, helping doctors learn more about how this disease changes over time. This study is currently recruiting patients and welcomes adults of all genders who meet the criteria.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 18 or above
- * Known ACLD, defined by:
- • LSM \> 10kPa or
- • Clinical cirrhosis, suggested by 1. ultrasonography of the hepatobiliary system shows features of cirrhosis (e.g. shrunken and nodular liver) and portal hypertension (e.g. dilated portal vein, portal-systemic collaterals or varices, splenomegaly, ascites). 2. Oesophagogastroduodenoscopy (OGD) shows presence of oesophageal varices (OV) and/or gastric varices (GV) and/or portal hypertensive gastropathy.
- Exclusion Criteria:
- • Current or past history of hepatocellular carcinoma (HCC)
- • History of liver transplantation
- • Asplenism or history of splenectomy
- • Serious medical illness with limited life expectancy of less than 6 months
- • Pregnancy
- • Unable to obtain or refusal of informed consent from patient
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Jimmy CT Lai, MB ChB
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported